BLAINTRAMUSCULARVIAL
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
4/8 — Partial
MYOBLOC (rimabotulinumtoxinb) by Design Pharmaceuticals is acetylcholine release inhibitors [moa]. First approved in 2000.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYOBLOC (rimabotulinumtoxinB) is a botulinum toxin type B product that inhibits acetylcholine release at the neuromuscular junction. It is administered intramuscularly and was approved in 2000 for clinical use. The drug works by blocking the release of acetylcholine, thereby reducing muscle contractions.
$0.915MPart D
LOE ApproachingThe product is approaching loss of exclusivity with minimal Part D spending ($915K in 2023), suggesting a contracted team focused on maintaining existing patient base rather than growth initiatives.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Started Nov 2021
272 enrolled
SpasticityCerebrovascular AccidentMultiple Sclerosis+3 more
Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects
Started Nov 2021
0Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Started Dec 2019
272 enrolled
Spasticity
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Started Oct 2015
187 enrolled
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
Started Nov 2013
187 enrolled
Sialorrhea
Worked on MYOBLOC at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.